Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients.

Xie Y, Sundström A, Maturi NP, Tan EJ, Marinescu VD, Jarvius M, Tirfing M, Jin C, Chen L, Essand M, Swartling FJ, Nelander S, Jiang Y, Uhrbom L.

J Pathol. 2018 Oct 25. doi: 10.1002/path.5186. [Epub ahead of print]

PMID:
30357839
2.

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.

Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini RM, Wikstrom KI, Essand M, Savoldo B, Hallböök H, Höglund M, Dotti G, Brenner MK, Hagberg H, Loskog A.

Clin Cancer Res. 2018 Aug 10. doi: 10.1158/1078-0432.CCR-18-0426. [Epub ahead of print]

PMID:
30097433
3.

Leukocyte Differentiation by Histidine-Rich Glycoprotein/Stanniocalcin-2 Complex Regulates Murine Glioma Growth through Modulation of Antitumor Immunity.

Roche FP, Pietilä I, Kaito H, Sjöström EO, Sobotzki N, Noguer O, Skare TP, Essand M, Wollscheid B, Welsh M, Claesson-Welsh L.

Mol Cancer Ther. 2018 Sep;17(9):1961-1972. doi: 10.1158/1535-7163.MCT-18-0097. Epub 2018 Jun 26.

PMID:
29945872
4.

CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.

Lugano R, Vemuri K, Yu D, Bergqvist M, Smits A, Essand M, Johansson S, Dejana E, Dimberg A.

J Clin Invest. 2018 Aug 1;128(8):3280-3297. doi: 10.1172/JCI97459. Epub 2018 Jun 25.

5.

Multiple nuclear-replicating viruses require the stress-induced protein ZC3H11A for efficient growth.

Younis S, Kamel W, Falkeborn T, Wang H, Yu D, Daniels R, Essand M, Hinkula J, Akusjärvi G, Andersson L.

Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3808-E3816. doi: 10.1073/pnas.1722333115. Epub 2018 Apr 2.

6.

Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models.

Fotaki G, Jin C, Kerzeli IK, Ramachandran M, Martikainen MM, Karlsson-Parra A, Yu D, Essand M.

Oncoimmunology. 2017 Dec 26;7(3):e1397250. doi: 10.1080/2162402X.2017.1397250. eCollection 2018.

7.

Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses.

Fotaki G, Jin C, Ramachandran M, Kerzeli IK, Karlsson-Parra A, Yu D, Essand M.

Oncoimmunology. 2017 Nov 27;7(3):e1395126. doi: 10.1080/2162402X.2017.1395126. eCollection 2018.

8.

Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice.

Martikainen M, Ruotsalainen J, Tuomela J, Härkönen P, Essand M, Heikkilä J, Hinkkanen A.

Br J Cancer. 2017 Jun 27;117(1):51-55. doi: 10.1038/bjc.2017.151. Epub 2017 May 30.

9.

The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.

Ramachandran M, Dimberg A, Essand M.

Semin Cancer Biol. 2017 Aug;45:23-35. doi: 10.1016/j.semcancer.2017.02.010. Epub 2017 Feb 28. Review.

10.

Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors.

Jin C, Yu D, Essand M.

Immunotherapy. 2016 Dec;8(12):1355-1361. doi: 10.2217/imt-2016-0125.

PMID:
28000533
11.

PATZ1 down-regulates FADS1 by binding to rs174557 and is opposed by SP1/SREBP1c.

Pan G, Ameur A, Enroth S, Bysani M, Nord H, Cavalli M, Essand M, Gyllensten U, Wadelius C.

Nucleic Acids Res. 2017 Mar 17;45(5):2408-2422. doi: 10.1093/nar/gkw1186.

12.

Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus.

Ramachandran M, Yu D, Dyczynski M, Baskaran S, Zhang L, Lulla A, Lulla V, Saul S, Nelander S, Dimberg A, Merits A, Leja-Jarblad J, Essand M.

Clin Cancer Res. 2017 Mar 15;23(6):1519-1530. doi: 10.1158/1078-0432.CCR-16-0925. Epub 2016 Sep 16.

13.

Heparanase Promotes Glioma Progression and Is Inversely Correlated with Patient Survival.

Kundu S, Xiong A, Spyrou A, Wicher G, Marinescu VD, Edqvist PD, Zhang L, Essand M, Dimberg A, Smits A, Ilan N, Vlodavsky I, Li JP, Forsberg-Nilsson K.

Mol Cancer Res. 2016 Dec;14(12):1243-1253. Epub 2016 Aug 26. Erratum in: Mol Cancer Res. 2018 Apr;16(4):740-741.

14.

Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer.

Yu D, Leja-Jarblad J, Loskog A, Hellman P, Giandomenico V, Oberg K, Essand M.

Neuroendocrinology. 2017;105(1):54-66. doi: 10.1159/000448430. Epub 2016 Jul 21.

PMID:
27442441
15.

Avidity characterization of genetically engineered T-cells with novel and established approaches.

Hillerdal V, Boura VF, Björkelund H, Andersson K, Essand M.

BMC Immunol. 2016 Jul 13;17(1):23. doi: 10.1186/s12865-016-0162-z.

16.

Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer.

Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D.

EMBO Mol Med. 2016 Jul 1;8(7):702-11. doi: 10.15252/emmm.201505869. Print 2016 Jul.

17.

HAdV-2-suppressed growth of SV40 T antigen-transformed mouse mammary epithelial cell-induced tumours in SCID mice.

Wu C, Cao X, Yu D, Huijbers EJ, Essand M, Akusjärvi G, Johansson S, Svensson C.

Virology. 2016 Feb;489:44-50. doi: 10.1016/j.virol.2015.11.031. Epub 2015 Dec 18.

18.

Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas.

Zhang L, Kundu S, Feenstra T, Li X, Jin C, Laaniste L, El Hassan TE, Ohlin KE, Yu D, Olofsson T, Olsson AK, Pontén F, Magnusson PU, Nilsson KF, Essand M, Smits A, Dieterich LC, Dimberg A.

Sci Signal. 2015 Dec 8;8(406):ra125. doi: 10.1126/scisignal.aaa1690.

PMID:
26645582
19.

Mesenchymal stromal cells support endothelial cell interactions in an intramuscular islet transplantation model.

Fransson M, Brännström J, Duprez I, Essand M, Le Blanc K, Korsgren O, Magnusson PU.

Regen Med Res. 2015 Sep 30;3:1. doi: 10.1186/s40340-015-0010-9. eCollection 2015.

20.

Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival.

Langenkamp E, Zhang L, Lugano R, Huang H, Elhassan TE, Georganaki M, Bazzar W, Lööf J, Trendelenburg G, Essand M, Pontén F, Smits A, Dimberg A.

Cancer Res. 2015 Nov 1;75(21):4504-16. doi: 10.1158/0008-5472.CAN-14-3636. Epub 2015 Sep 11.

21.

Other Novel Therapies: Biomarkers, microRNAs and microRNA Inhibitors, DNA Methylation, Epigenetics, Immunotherapy and Virotherapy.

Giandomenico V, Thirlwell C, Essand M.

Front Horm Res. 2015;44:248-62. doi: 10.1159/000403885. Epub 2015 Aug 14. Review.

PMID:
26303717
22.

Correction: Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration.

Ramachandran M, Jin C, Yu D, Eriksson F, Essand M.

J Immunol. 2015 Jun 1;194(11):5568. doi: 10.4049/jimmunol.1500649. No abstract available.

23.

Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.

Hillerdal V, Essand M.

BioDrugs. 2015 Apr;29(2):75-89. doi: 10.1007/s40259-015-0122-9. Review.

24.

Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration.

Ramachandran M, Jin C, Yu D, Eriksson F, Essand M.

J Immunol. 2014 Sep 1;193(5):2287-96. doi: 10.4049/jimmunol.1400339. Epub 2014 Jul 21. Erratum in: J Immunol. 2015 Jun 1;194(11):5568.

25.

Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer.

Schenk E, Essand M, Kraaij R, Adamson R, Maitland NJ, Bangma CH.

Hum Gene Ther Clin Dev. 2014 Mar;25(1):7-15. doi: 10.1089/humc.2013.181.

PMID:
24649837
26.

A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells.

Liljenfeldt L, Yu D, Chen L, Essand M, Mangsbo SM.

J Immunother. 2014 Apr;37(3):155-62. doi: 10.1097/CJI.0000000000000028.

PMID:
24598450
27.

Pre-clinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer.

Schenk E, Essand M, Kraaij R, Adamson R, Maitland N, Bangma CH.

Hum Gene Ther Clin Dev. 2014 Feb 18. [Epub ahead of print]

PMID:
24548052
28.

Immunological shielding by induced recruitment of regulatory T-lymphocytes delays rejection of islets transplanted in muscle.

Vågesjö E, Christoffersson G, Waldén TB, Carlsson PO, Essand M, Korsgren O, Phillipson M.

Cell Transplant. 2015;24(2):263-76. doi: 10.3727/096368914X678535. Epub 2014 Jan 29.

PMID:
24480306
29.

Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.

Hillerdal V, Ramachandran M, Leja J, Essand M.

BMC Cancer. 2014 Jan 18;14:30. doi: 10.1186/1471-2407-14-30.

30.

Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors.

Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M.

Mol Ther Methods Clin Dev. 2014 Mar 5;1:14001. doi: 10.1038/mtm.2014.1. eCollection 2014.

31.

Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.

Jin C, Yu D, Čančer M, Nilsson B, Leja J, Essand M.

Hum Gene Ther. 2013 Aug;24(8):766-75. doi: 10.1089/hum.2012.132.

32.

An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors.

Ramachandran M, Yu D, Wanders A, Essand M, Eriksson F.

Mol Ther. 2013 Nov;21(11):2008-18. doi: 10.1038/mt.2013.153. Epub 2013 Jul 2.

33.

Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.

Karlsson H, Lindqvist AC, Fransson M, Paul-Wetterberg G, Nilsson B, Essand M, Nilsson K, Frisk P, Jernberg-Wiklund H, Loskog A.

Cancer Gene Ther. 2013 Jul;20(7):386-93. doi: 10.1038/cgt.2013.35. Epub 2013 Jun 21. Erratum in: Cancer Gene Ther. 2013 Dec;20(12):702. Karlsson, S C H [corrected to Karlsson, H];Loskog, S I A [corrected to Loskog, A].

PMID:
23788110
34.

Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures.

Yu D, Jin C, Ramachandran M, Xu J, Nilsson B, Korsgren O, Le Blanc K, Uhrbom L, Forsberg-Nilsson K, Westermark B, Adamson R, Maitland N, Fan X, Essand M.

PLoS One. 2013;8(1):e54952. doi: 10.1371/journal.pone.0054952. Epub 2013 Jan 25.

35.

Genetically engineered T cells for the treatment of cancer.

Essand M, Loskog AS.

J Intern Med. 2013 Feb;273(2):166-81. doi: 10.1111/joim.12020. Review.

36.

Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation.

Muthana M, Rodrigues S, Chen YY, Welford A, Hughes R, Tazzyman S, Essand M, Morrow F, Lewis CE.

Cancer Res. 2013 Jan 15;73(2):490-5. doi: 10.1158/0008-5472.CAN-12-3056. Epub 2012 Nov 20.

37.

T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells.

Hillerdal V, Nilsson B, Carlsson B, Eriksson F, Essand M.

Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15877-81. Epub 2012 Sep 10.

38.

CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.

Fransson M, Piras E, Burman J, Nilsson B, Essand M, Lu B, Harris RA, Magnusson PU, Brittebo E, Loskog AS.

J Neuroinflammation. 2012 May 30;9:112. doi: 10.1186/1742-2094-9-112.

39.

Islet engraftment and revascularization in clinical and experimental transplantation.

Molnár C, Essand M, Wennberg L, Berne C, Larsson E, Tufveson G, Korsgren O.

Cell Transplant. 2013;22(2):243-51. doi: 10.3727/096368912X640637. Epub 2012 May 8.

PMID:
22584061
40.

Virotherapy of neuroendocrine tumors.

Essand M.

Neuroendocrinology. 2013;97(1):26-34. doi: 10.1159/000336084. Epub 2012 Feb 29. Review.

PMID:
22378183
41.

Age-related somatic structural changes in the nuclear genome of human blood cells.

Forsberg LA, Rasi C, Razzaghian HR, Pakalapati G, Waite L, Thilbeault KS, Ronowicz A, Wineinger NE, Tiwari HK, Boomsma D, Westerman MP, Harris JR, Lyle R, Essand M, Eriksson F, Assimes TL, Iribarren C, Strachan E, O'Hanlon TP, Rider LG, Miller FW, Giedraitis V, Lannfelt L, Ingelsson M, Piotrowski A, Pedersen NL, Absher D, Dumanski JP.

Am J Hum Genet. 2012 Feb 10;90(2):217-28. doi: 10.1016/j.ajhg.2011.12.009. Epub 2012 Feb 2.

42.

Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Yu D, Jin C, Leja J, Majdalani N, Nilsson B, Eriksson F, Essand M.

J Virol. 2011 Dec;85(24):13114-23. doi: 10.1128/JVI.05759-11. Epub 2011 Sep 28.

43.

In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus.

Adamson RE, Frazier AA, Evans H, Chambers KF, Schenk E, Essand M, Birnie R, Mitry RR, Dhawan A, Maitland NJ.

Hum Gene Ther. 2012 Feb;23(2):218-30. doi: 10.1089/hum.2011.021. Epub 2011 Sep 9.

PMID:
21823897
44.

Oncolytic viruses for the treatment of neuroendocrine tumors.

Essand M, Leja J, Giandomenico V, Oberg KE.

Horm Metab Res. 2011 Nov;43(12):877-83. doi: 10.1055/s-0031-1277225. Epub 2011 May 30. Review.

PMID:
21626470
45.

Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.

Leja J, Yu D, Nilsson B, Gedda L, Zieba A, Hakkarainen T, Åkerström G, Öberg K, Giandomenico V, Essand M.

Gene Ther. 2011 Nov;18(11):1052-62. doi: 10.1038/gt.2011.54. Epub 2011 Apr 14.

PMID:
21490682
46.

The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication.

Danielsson A, Dzojic H, Rashkova V, Cheng WS, Essand M.

PLoS One. 2011 Feb 17;6(2):e14700. doi: 10.1371/journal.pone.0014700.

47.

Use of macrophages to target therapeutic adenovirus to human prostate tumors.

Muthana M, Giannoudis A, Scott SD, Fang HY, Coffelt SB, Morrow FJ, Murdoch C, Burton J, Cross N, Burke B, Mistry R, Hamdy F, Brown NJ, Georgopoulos L, Hoskin P, Essand M, Lewis CE, Maitland NJ.

Cancer Res. 2011 Mar 1;71(5):1805-15. doi: 10.1158/0008-5472.CAN-10-2349. Epub 2011 Jan 13.

48.

An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood.

Danielsson A, Elgue G, Nilsson BM, Nilsson B, Lambris JD, Tötterman TH, Kochanek S, Kreppel F, Essand M.

Gene Ther. 2010 Jun;17(6):752-62. doi: 10.1038/gt.2010.18. Epub 2010 Mar 11.

PMID:
20220781
49.

Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability.

Leja J, Nilsson B, Yu D, Gustafson E, Akerström G, Oberg K, Giandomenico V, Essand M.

PLoS One. 2010 Jan 27;5(1):e8916. doi: 10.1371/journal.pone.0008916.

50.

Gene transfer vectors targeted to human prostate cancer: do we need better preclinical testing systems?

Maitland N, Chambers K, Georgopoulos L, Simpson-Holley M, Leadley R, Evans H, Essand M, Danielsson A, van Weerden W, de Ridder C, Kraaij R, Bangma CH; GIANT FP6 Consortium.

Hum Gene Ther. 2010 Jul;21(7):815-27. doi: 10.1089/hum.2009.210. Review.

PMID:
20030557

Supplemental Content

Loading ...
Support Center